Discovery of small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase

Supreet Kaur, Nicholas S. Nieto, Peter McDonald, Josh R. Beck, Richard B. Honzatko, Anuradha Roy & Scott W. Nelson

To cite this article: Supreet Kaur, Nicholas S. Nieto, Peter McDonald, Josh R. Beck, Richard B. Honzatko, Anuradha Roy & Scott W. Nelson (2022) Discovery of small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase, Journal of Enzyme Inhibition and Medicinal Chemistry, 37:1, 1320-1326, DOI: 10.1080/14756366.2022.2070909

To link to this article: https://doi.org/10.1080/14756366.2022.2070909

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

View supplementary material

Published online: 05 May 2022.

Submit your article to this journal

Article views: 535

View related articles

View Crossmark data
Discovery of small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase

Supreet Kaur, Nicholas S. Nieto, Peter McDonald, Josh R. Beck, Richard B. Honzatko, Anuradha Roy and Scott W. Nelson

ABSTRACT
Malaria is caused by infection with protozoan parasites of the Plasmodium genus, which is part of the phylum Apicomplexa. Most organisms in this phylum contain a relic plastid called the apicoplast. The apicoplast genome is replicated by a single DNA polymerase (apPOL), which is an attractive target for anti-malarial drugs. We screened small-molecule libraries (206,504 compounds) using a fluorescence-based high-throughput DNA polymerase assay. Dose/response analysis and counter-screening identified 186 specific apPOL inhibitors. Toxicity screening against human HepaRG human cells removed 84 compounds and the remaining were subjected to parasite killing assays using chloroquine resistant P. falciparum parasites. Nine compounds were potent inhibitors of parasite growth and may serve as lead compounds in efforts to discover novel malaria drugs.

Introduction
Malaria kills over half a million people each year with the majority of those deaths occurring in children under five years of age. Over 40% of the world’s population live in areas where Malaria is a serious health risk with more than 215 million new cases diagnosed each year. During the last century, Malaria was controlled with chloroquine, but resistance emerged in the 1950s, starting in Southeast Asia, then spreading throughout Asia, and finally Africa. Artemisinin and its derivatives are current drugs of choice and are especially effective in slow-acting anti-malarial drugs. In 2005, partial resistance to artemisinin arose in parasites from Cambodia, Myanmar, Thailand and Viet Nam. Parasites resistant to artemisinin-based therapies are now prevalent in Southeast Asia and are emerging in Africa, jeopardising global programs to control Malaria. New drugs targeting novel parasite biology may play a critical role in curbing the impact of this disease.

Malaria is caused by parasites of the genus Plasmodium in the phylum Apicomplexa. Nearly all organisms within this phylum contain an unusual organelle called the apicoplast. The apicoplast is evolutionarily related to the plastid and participates in several metabolic pathways, including the biosynthesis of fatty acids, haem, iron-sulfur clusters, and isoprenoids. The parasite relies on the apicoplast for the synthesis of isoprenoids. Defects in apicoplast metabolism, or its failure to replicate and divide, lead to the death of Plasmodium at the blood and liver stages of infection. Hence, the apicoplast is a promising drug target. Nearly 600 proteins exist within the apicoplast and approximately 4% of those are involved in replication of the 35 kb apicoplast genome. Enzymes that carry-out the fundamental process of DNA replication are promising drug targets. Indeed, ciprofloxacin, a DNA type II topoisomerase inhibitor, has anti-malarial activity; however, antiparasitic properties could be due to off-target effects instead of, or as well as, inhibition of the P. falciparum gyrase. The apicoplast DNA polymerase (apPOL) represents an attractive target for anti-malarial drug development. apPOL exhibits low amino-acid sequence identity to replicative polymerases from other species. Outside of Apicomplexa, the nearest homolog (35% sequence identity) is the replicative polymerase from the cyanobacteria Cyanothece sp. PCC 8802. The most similar human DNA polymerases are the lesion bypass polymerases theta and nu (23% and 22% sequence identity, respectively), with the other human DNA polymerases displaying less than 20% identity, providing a foundation for selectivity. On the other hand, apPOLs from the two primary causative agents of human Malaria (P. falciparum and P. vivax) are 84% sequence identical, suggesting that drugs targeting P. falciparum apPOL would be effective in treating Malaria caused by P. vivax. To discover novel inhibitors of P. falciparum apPOL (hereafter, Pf-apPOL), we screened several commercial small-molecule libraries using a fluorescence-based high-throughput DNA polymerase assay. The primary hits were subjected to dose/response analysis and counter-screening against bacteriophage T4 DNA polymerase to remove non-specific inhibitors and compounds that interfered with the assay. The specific Pf-apPOL inhibitors (186) were screened for toxicity against human cells and non-toxic compounds (102) were tested in parasite killing assays using chloroquine resistant P. falciparum parasites cultured in human red blood cells.

ARTICLE HISTORY
Received 12 February 2022
Revised 21 April 2022
Accepted 22 April 2022

KEYWORDS
Malaria; high-throughput screening; DNA polymerase; apicoplast

CONTACT
Scott W. Nelson, Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, IA, USA
Scott.W.Nelson@iastate.edu

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

https://doi.org/10.1080/14756366.2022.2070909
blood cells. Ultimately, nine inhibitors passed all screens and arrested parasite growth in human red blood cells.

Materials and methods

Materials and reagents
Codon-optimized, exonuclease-deficient Pf-apPOL was overexpressed in E. coli BL21 (DE3) and purified as described15. The protein was dialysed against two, 1-liter changes of 50 mM Tris-acetate (pH 8.0), 400 mM NaCl, and 20% glycerol. Plasmodium berghei and Babesia bovis apPOLS (Pb-apPOL and Bb-apPOL, respectively) were codon-optimized, expressed, and purified as for Pf-apPOL15. Bacteriophage T4 DNA polymerase was purified as described16. The DNA oligonucleotides used to make the high-throughput substrate were obtained from Integrated DNA Technologies. Deoxynucleotides were purchased from Strategene. All other materials came from Fisher Scientific.

High-throughput (HT) assay

The HT assay employs a molecular beacon, a stem-loop DNA template with a Cy3 dye and the Black Hole Quencher on the 3′ and 5′ ends of the DNA, respectively15. Pf-apPOL concentration is based on a calculated absorptivity of \( \varepsilon = 56750 \text{ M}^{-1} \text{cm}^{-1} \). Reactions were carried out at 25°C, using Corning 3575 386-well plates (well-volume, 20 \( \mu \)L). Assays testing for compound inhibition composed of reaction buffer (pH 7.9 in 50 mM potassium acetate, 20 mM Tris-acetate and 10 mM magnesium acetate), Pf-apPOL (20 nM), DNA substrate (20 nM), dNTPs (6 \( \mu \)M), and compound (10 \( \mu \)M in DMSO). The fluorescence of each well was determined using a BioTek Synergy Neo fluorescence plate reader using excitation and emission wavelengths of 555 and 570 nm, respectively. The % inhibition was determined using Equation (1):

\[
\text{% Inhibition} = 100 \left( \frac{\text{Test} - \text{Min}}{\text{Max} - \text{Min}} \right) \times 100
\]  

In the above, \( \text{Min} \) is the average of fluorescence emission of the negative controls (substrate only), \( \text{Max} \) the average fluorescence emission from the positive controls (enzyme + substrate), and \( \text{Test} \) the emission from the assays in the presence of compounds (enzyme + compound + substrates). Dose-response confirmation assays were performed under similar conditions as the primary screen, but monitoring fluorescence at 10, 90, and 180 min. Tested concentrations of compounds were 2.5, 10, 20, 40, and 80 \( \mu \)M. The \( IC_{50} \) of each compound was determined using Equation (2):

\[
IC_{50} = \frac{V_{\text{Max}}}{1 + \left( \frac{C}{IC_{50}} \right)^n}
\]  

In the above, \( n \) measures cooperativity, with \( n > 1 \) indicating synergistic binding of more than a single molecule of the compound.

Parasite growth inhibition assay

The chloroquine resistant P. falciparum parasites (strain Dd2) were cultured in de-identified, IRB-exempt human red blood cells (RBCs) obtained from the American Red Cross and parasite cultures were maintained as described17. Parasitaemia (percentage of total RBCs infected) was measured by flow cytometry on an Attune NxT (ThermoFisher) by nucleic-acid staining of cultured RBCs with phosphate-buffered saline (PBS) containing 0.8 \( \mu \)g ml\(^{-1} \) acridine orange. We began by determining percent growth inhibition at single compound dose (20 \( \mu \)M) for the 102 non-toxic compounds. Those that inhibited parasite growth by 50% or more were subjected to dose response analysis to extract \( EC_{50} \) values. The
experiments were initiated with a starting parasitaemia of ~1% and parasitaemia was measured 72 and 96 h post compound addition. Growth was normalised to parasite cultures with carrier only (DMSO).

**Results and discussion**

**High-throughput screening of small molecule libraries to identify inhibitors of apPOL**

To identify apPOL inhibitors we utilised our previously developed high-throughput DNA polymerase assay\(^{15}\). The HT assay is based on a molecular beacon DNA template that forms a stem-loop with a Cy3 dye and the Black Hole Quencher on the 3’ ends of the DNA, respectively. DNA polymerase activity extends an annealed primer through the stem region, displacing the fluorophore from the quencher, thereby increasing its fluorescence (Figure 1(A)). The assay accurately recapitulates the kinetic behaviour of apPOL, as measured through more conventional low-throughput gel-based assays\(^{18}\). The Z’ factor for the assay described here was 0.9 across all plates (data not shown).

The initial screen followed the workflow outlined in Figure 1(B). The identity of the compound libraries screened and the resulting primary hits are given in Table 1 with a scattergram of the percent inhibition for each well shown in Figure 2. A total of 206,504 compounds were tested for inhibition of Pf-apPOL with 1217 compounds qualifying as “hits” for an overall rate of 0.59%. Natural products and natural product-like compounds were overrepresented in the hit subgroup, with rates of 4.8% for the GreenPharma natural product library and 1.4% for the Life Chemicals natural product-like library. Also overrepresented (2.7%) was the Sigma Lopac 1280 library, which contains exclusively pharmacologically active compounds.

Each compound was tested in a dose-response format to determine IC\(_{50}\) values. Out of the 1217 compounds identified as hits, 979 exhibited potential inhibition in dose-response reconfirmation assays (80.4%). These compounds were structurally diverse with only 8 clusters containing 10 or more compounds (Supplemental Figure S1). Example dose-response data for clusters with relatively high and low affinities are shown in Supplemental Figures S2 and S3, respectively. The 979 compounds likely include some that interfere with the fluorescent read-out of the assay (false positives). Additionally, many of the identified compounds resemble DNA mimics or nucleotide analogs and are likely non-specific inhibitors of nucleic-acid polymerases and enzymes that bind nucleic acids. To identify compounds that specifically inhibit *P. falciparum* apPOL, we screened the 979 potential inhibitors against bacteriophage T4 DNA polymerase\(^{19}\). T4 DNA polymerase can be produced in large quantities, and is in the same family (B-family) as the replicative human DNA polymerases (\(\alpha, \delta, \text{ and } \epsilon\))\(^{20}\). The majority of the 979 compounds (793) inhibited T4 DNA polymerase. Further investigation of these non-selective inhibitors of DNA polymerase could reveal modes of inhibition that are common across multiple DNA polymerase families. The remaining compounds (186) represent “primary” hits, that is, specific inhibitors of *P. falciparum* apicoplast DNA polymerase. On the basis of cluster analysis, primary hits are structurally diverse with only two clusters containing 10 or more compounds (Supplemental Figure S4). The vast majority of the compounds (94%) do not violate any of the Lipinski’s rule of five (Supplemental Figure S4 and file 1).

**Table 1. Results from high-throughput screening to identify inhibitors of *P. falciparum* apicoplast DNA polymerase.**

| Library                        | Total # of Compounds | # of Hits | Hit Rate | Dose-response reconfirmation (# of compounds) | Reconfirmation rate, % |
|--------------------------------|----------------------|-----------|----------|-----------------------------------------------|------------------------|
| Chembridge Diversity           | 43736                | 250       | 0.57     | 205                                           | 82                     |
| ChemDiv Diversity              | 56232                | 293       | 0.52     | 267                                           | 91                     |
| CMLD                           | 5208                 | 22        | 0.42     | 21                                            | 96                     |
| Life Diversity                 | 15040                | 64        | 0.43     | 54                                            | 84                     |
| GreenPharma Natural Products   | 480                  | 23        | 4.79     | 20                                            | 87                     |
| Life Chemicals Nature Product-like | 8128           | 114       | 1.4      | 71                                            | 62                     |
| ChemDiv CNS                    | 26136                | 120       | 0.46     | 102                                           | 85                     |
| ChemDiv BFL/PPL                | 33864                | 61        | 0.18     | 53                                            | 87                     |
| Sigma Lopac                    | 1280                 | 35        | 2.73     | 27                                            | 77                     |
| Maybridge Hit finder 2016      | 14400                | 217       | 1.51     | 148                                           | 68                     |
| Maybridge MiniHitFinder 2016   | 2000                 | 18        | 0.9      | 11                                            | 61                     |
| **Total**                      | 206504               | 1217      | 0.59     | 979                                           | 80                     |
| **Average Hit Rate (%)**       |                      |           |          |                                               |                        |

**Toxicity of the primary hits towards human cells**

As a measurement of toxicity, we employed the well-established CellTiter-Glo\textsuperscript{TM} Luminescent Cell Viability Assay using HepaRG human cells. These cells contain endogenous luciferase enzyme that uses ATP and d-Luciferin to produce excited oxyluciferin, which then returns to its ground state by the emission of a photon (luminescence). Metabolically active cells generate ATP, hence luminescence is proportional to ATP present and an indication of cellular metabolic activity. The assay is robust, sensitive, reproducible, and routinely used in a high-throughput format at the KUHITS facility\(^{21}\). The results from the 48 h cytotoxicity assay indicate that 102 of the 186 primary hits are non-toxic to the human hepatic cells (55%) at the highest concentration tested (100 \(\mu\)M). Cluster analysis indicates 68 groups of non-similar compounds, including clusters of 10 and 12 from the set of 186 apPOL-specific inhibitors (Figure 3). In addition to analysing the compounds for Lipinski violations, we also used SwissADME to determine the synthetic accessibility score and lead-likeness score for each compound\(^{23}\). The synthetic accessibility score ranges from 1 (very easy) to 10 (very hard) and has been shown to correlate well with manual estimations of synthetic difficulty performed by chemists\(^{24}\). The majority of the compounds appear to be synthetically tractable with scores ranging from 2–4 and only 7 molecules scoring above 4.0 (Figure 4). Lead-likeness is determined through a combination of physiochemical filters (e.g. PAINS\(^{25}\) and Brenk\(^{26}\)), and the notion that selection criteria for lead compounds should emphasise low molecular weights (100–350 Da) and degree of polarity (clogP) values of 1–3.0 because optimisation of leads generally increase size and lipophilicity. As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules\(^{23,27}\). From the set of 102 non-toxic apPOL inhibitors, 30 compounds have no lead-likeness violations and another 31 compounds only violate a single criterion, indicating that the majority of these compounds are potential leads.
Lethality of compounds towards cultured *P. falciparum* parasites

We tested the ability of the 102 compounds to kill *P. falciparum* parasites cultured in human red blood cells. Due to the number of compounds, we used a single inhibitor concentration of 20 μM and performed experiments in triplicate. These single-dose assays identified 9 compounds that inhibited parasite growth by more than 50%. These compounds were then tested in a dose-response format against chloroquine resistant *P. falciparum* parasites (Dd2) and the resulting data were fit to a sigmoidal growth inhibition curve to determine EC50 values (Figure 5, Table 2). Additionally, these compounds were tested for *in vitro* inhibition of *P. berghei* (Pb) and *Babesia bovis* (Bb) apicoplast DNA polymerases, which are 82% and 43% identical to the *P. falciparum* protein, respectively. Inhibition of Pb-apPOL is a desired feature because it is likely that future *in vivo* studies will be performed in the mouse model for Malaria. Inhibition of Bb-apPOL, but not the more distantly related B-family polymerase T4 DNA pol, would suggest that the inhibitor may be pan-selective against most apicoplast apPOL’s. The *in vitro* polymerase assays identified 5 compounds that were potent inhibitors of all three apicoplast polymerases and a single compound that inhibited Pf-apPOL and Bb-apPOL but not Pb-apPOL (Table 2). Finally, to determine if the compounds were killing the parasites solely via apicoplast disruption28, the dose-response curves were also performed with 1 mM isopentylpyrophosphate (IPP) in the growth media (Table 2). As seen in Table 2, none of the compounds display a significant IPP effect, suggesting that these compounds are hitting multiple cellular targets (e.g. apPOL and a non-apicoplast protein) or a specific non-apicoplast target. At this time, it is unclear what the non-apicoplast target(s) may be. One intriguing possibility is that these compounds may be targeting both the apicoplast and the mitochondrial DNA polymerases. Very little is known regarding mitochondrial DNA replication in *P. falciparum*; however, signal sequence identification algorithms have predicted that the other bacterial A-family DNA polymerase residing in *P. falciparum* is targeted to the mitochondria (PF3D7_0625300)29. As five of these Pf-apPOL inhibitors have the ability to inhibit the distantly related Bb-apPOL, it would not be
Figure 4. Potential as lead compounds. A plot of the synthetic accessibility versus leadlikeness violations for the non-toxic, specific apPOL inhibitors is shown. Each compound is labelled with a number corresponding to the data in Supplemental file 1. The markers are coloured according to their IC50 values and the number of Lipinski violations are indicated by marker shape. A description of synthetic accessibility and leadlikeness can be found in the main text.

Figure 5. Compounds active against cultured *Plasmodium falciparum*. A plot of IC50 values versus EC50 values is shown. The markers are coloured according to their Druglikeness values as calculated by the DataWarrior22 software package. The number of Lipinski violations are indicated by marker shape.
surprising if they also inhibited the only other A-family polymerase in \( P. \) \text{falciparum}. The mitochondrion has been recognised as a promising drug target\(^{30,31}\) and saturating transposon mutagenesis in \( P. \) \text{falciparum}\(^{32}\) as well as pooled knockout screens in \( P. \) \text{berghii}\(^{33}\) indicate that this A-family polymerase is likely essential. We are currently in the process of cloning and expressing this putative mitochondrial DNA polymerase to determine the effect of these compounds on its activity. If inhibition of the mitochondrial DNA polymerase is confirmed, these compounds would have very high potential for further development, since dual targeting both DNA polymerases residing within the parasite would increase potency and reduce the evolution of drug resistance.

**Conclusions**

Resistance to current Malaria drugs is inevitable and new drugs that target novel aspects of \( P. \) \text{falciparum}’s biology are necessary to combat the disease. The apicoplast is a validated drug target and inhibition of apicoplast DNA replication leads to the loss of the organelle and parasite death\(^{34}\). The large-scale high-throughput screen described here defined several sets of compounds that could serve as tools to investigate mechanisms of DNA polymerase inhibition or as lead compounds for further optimisation into anti-malaria drugs. Future work will involve determining mechanisms of inhibition, apPOL binding sites, and target(s) confirmation.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was supported by the National Institutes of Health under Grants [R21AI27622, P20GM113117, and P30CA168524-09].

**References**

1. Organization, W. H., World Malaria Report 2020. 2020.
2. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001;184:770–6.
3. Wongsrichanalai C, Sibley CH. Fighting drug-resistant Plasmodium falciparum: the challenge of artemisinin resistance. Clin Microbiol Infect 2013;19:908–16.
4. White NJ. Antimalarial drug resistance. J Clin Investig 2004;113:1084–92.
5. Burrows JN, Leroy D, Lortharius J, Waterson D. Challenges in antimalarial drug discovery. Future Med Chem 2011;3:1401–12.
6. Uvimana A, Umulisa N, Venkatesan M, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis 2021;21:1120–8.
7. Balikagala B, Fukuda N, Ikeda M, et al. Evidence of artemisinin-resistant Malaria in Africa. N Engl J Med 2021;385:1163–71.
8. Kalanon M, McFadden GI. Malaria, Plasmodium falciparum and its apicoplast. Biochem Soc Trans 2010;38:775–82.
9. Seeber F, Soldati-Favre D. Metabolic pathways in the apicoplast of apicomplexa. Int Rev Cell Mol Biol 2010;281:161–228.
10. Yeh E, Derisi JL. Chemical Rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol 2011;9:e1001138.
11. Dahl EL, Rosenthal PJ. Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol 2008;24:279–84.
12. Ralph SA, van Dooren GG, Waller RF, et al. Tropical infectious diseases: metabolic maps and functions of the Plasmodium falciparum apicoplast. Nat Rev Microbiol 2004;2:203–16.
13. Girdwood SCT, Nenortas E, Shapiro TA. Targeting the gyrase of Plasmodium falciparum with topoisomerase poisons. Biochem Pharmacol 2015;95:227–37.
14. Seew F, Sato S, Janssen CS, et al. The plastidic DNA replication enzyme complex of Plasmodium falciparum. Mol Biochem Parasitol 2005;141:45–53.
15. Miller ME, Parrott E, Singh R, Nelson SW. A high-throughput assay to identify inhibitors of the apicoplast DNA polymerase from plasmodium falciparum. J Biomol Screen 2014;19:966–72.
16. Yang J, Trakselis MA, Roccasecca RM, et al. The application of a minicircle substrate in the study of the coordinated T4 DNA replication. J. Biol. Chem 2020;295:14595–601.
17. Nessel T, Beck JM, Rayatpisheh S, et al. EXP1 is required for Plasmodium falciparum apicoplast. Nat Rev Microbiol 2004;2:145–53.
18. Wingert BM, Parrott EE, Nelson SW. Fidelity, mismatch extension, and proofreading activity of the Plasmodium falciparum apicoplast DNA polymerase. Biochemistry 2013;52:7723–30.
19. Nelson SW, Zhuang Z, Sperling MM, Benkovic SJ, T4 phage replisome. Viral Genome Replication. 2009.
20. Jain R, Aggarwal AK, Rechkobit O. Eukaryotic DNA polymerases. Curr Opin Struct Biol 2018;53:77–87.
21. Petersson KR, Costa FC, Fedosyuk H, et al. A cell-based high-throughput screen for novel chemical inducers of fetal hemoglobin for treatment of hemoglobinopathies. PLoS One 2014;9:e107006.

**Table 2.** Inhibition data for compounds found to be active against cultured \( P. \) \text{falciparum}.

| Molecule | KUID | IC\(_{50}\) Pf-apPOL (µM) | IC\(_{50}\) Pb-apPOL (µM) | IC\(_{50}\) Bb-apPOL (µM) | EC\(_{50}\) (µM) | EC\(_{50}\) + IPP (µM) |
|---------|------|------------------------|------------------------|------------------------|-------------|------------------------|
| 1       | KU0263501 | 5.0 ± 0.9 | 7.1 ± 0.6 | 3.7 ± 0.2 | 8.6 ± 0.4 | 9.3 ± 0.5 |
| 21      | KU0036696 | 8 ± 1 | 9.7 ± 1.6 | 8 ± 2 | 3.1 ± 0.1 | 3.4 ± 0.1 |
| 27      | KU0260920 | 15 ± 1 | ND | 10 ± 1 | 9 ± 1 |
| 31      | KU0007309 | 15 ± 1 | ND | 15 ± 5 | 8.9 ± 0.5 | 8.7 ± 0.6 |
| 34      | KU0241474 | 7.2 ± 0.9 | ND | 11.3 ± 0.9 | 10.0 ± 0.7 |
| 55      | KU0177470 | 10 ± 2 | 51.9 ± 3.5 | 1.5 ± 1.0 | 3.5 ± 0.3 | 4.3 ± 0.2 |
| 94      | KU0261556 | 7.6 ± 0.6 | 13.9 ± 1.6 | 30 ± 3 | 4.6 ± 0.2 | 3.7 ± 0.5 |
| 95      | KU0001071 | 7.4 ± 0.4 | 8.6 ± 0.7 | 2.5 ± 0.2 | 7.5 ± 0.5 | 7.4 ± 0.4 |
| 98      | KU0271653 | 8 ± 2 | ND | 16 ± 1 | 11 ± 1 |
22. Sander T, Freyss J, von Korff M, Rufener C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J Chem Inf Model 2015;55:460–73.
23. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
24. Ertl P, Schuffenhauer A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform 2009;1:8.
25. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719–40.
26. Brenk R, Schipani A, James D, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem 2008;3:435–44.
27. Hann MM, Keseru GM. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov 2012;11:355–65.
28. Milton ME, Nelson SW. Replication and maintenance of the Plasmodium falciparum apicoplast genome. Mol Biochem Parasitol 2016;208:56–64.
29. Vaidya AB, Mather MW. Mitochondrial evolution and functions in malaria parasites. Annu Rev Microbiol 2009;63:249–67.
30. Goodman CD, Buchanan HD, McFadden GI. Is the mitochondrion a good malaria drug target? Trends Parasitol 2017;33:185–93.
31. Kumar S, Bhardwaj TR, Prasad DN, Singh RK. Drug targets for resistant malaria: historic to future perspectives. Biomed Pharmacother 2018;104:8–27.
32. Zhang M, Wang C, Otto TD, et al. Uncovering the essential genes of the human malaria parasite Plasmodium falciparum by saturation mutagenesis. Science 2018;360:eaap7847.
33. Bushell E, Gomes AR, Sanderson T, et al. Functional profiling of a Plasmodium genome reveals an abundance of Essential Genes. Cell 2017;170:260–72.
34. Low LM, Stanisic DI, Good MF. Exploiting the apicoplast: apicoplast-targeting drugs and malaria vaccine development. Microbes Infect 2018;20:477–83.